JP2010513435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513435A5 JP2010513435A5 JP2009542195A JP2009542195A JP2010513435A5 JP 2010513435 A5 JP2010513435 A5 JP 2010513435A5 JP 2009542195 A JP2009542195 A JP 2009542195A JP 2009542195 A JP2009542195 A JP 2009542195A JP 2010513435 A5 JP2010513435 A5 JP 2010513435A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- hydrogen
- ring
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- -1 -OR 9 Chemical group 0.000 claims 1
- FWFABQINPRGOOH-HMZWWLAASA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2H-tetrazol-5-ylmethyl)pyrazole-3-carboxylic acid (1R)-N-methyl-1-[4-(trifluoromethoxy)phenyl]ethanamine Chemical compound C[C@H](C(C=C1)=CC=C1OC(F)(F)F)NC.OC(C(C(CC1=NN=NN1)=C1C(C=C2)=CC=C2Cl)=NN1C(C=CC=C1)=C1Cl)=O FWFABQINPRGOOH-HMZWWLAASA-N 0.000 claims 1
- ZRXDEDIUKOZYJZ-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)-n-[(1r)-1-[3-(trifluoromethyl)phenyl]ethyl]pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC1=NN=NN1 ZRXDEDIUKOZYJZ-OAHLLOKOSA-N 0.000 claims 1
- JKLSGJJVZPRNDK-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)-n-[(1r)-1-[4-(trifluoromethoxy)phenyl]ethyl]pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 JKLSGJJVZPRNDK-OAHLLOKOSA-N 0.000 claims 1
- DANBLBWVACCFGQ-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)-n-[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 DANBLBWVACCFGQ-OAHLLOKOSA-N 0.000 claims 1
- DISPWRFTNSDJNJ-CQSZACIVSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-n-[(1r)-1-(3,4-dichlorophenyl)ethyl]-4-(2h-tetrazol-5-ylmethyl)pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 DISPWRFTNSDJNJ-CQSZACIVSA-N 0.000 claims 1
- CZGTZPBJMUIHQR-OAHLLOKOSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-n-[(1r)-1-(3-fluorophenyl)ethyl]-4-(2h-tetrazol-5-ylmethyl)pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(F)C=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC1=NN=NN1 CZGTZPBJMUIHQR-OAHLLOKOSA-N 0.000 claims 1
- LOVAGEWSHISHOL-OAHLLOKOSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-[[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]carbamoyl]pyrazol-4-yl]acetic acid Chemical compound N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C(C=1CC(O)=O)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 LOVAGEWSHISHOL-OAHLLOKOSA-N 0.000 claims 1
- BUNZMHKUTFMZHO-MRXNPFEDSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-[methyl-[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]carbamoyl]pyrazol-4-yl]acetic acid Chemical compound CN([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C(C=1CC(O)=O)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 BUNZMHKUTFMZHO-MRXNPFEDSA-N 0.000 claims 1
- XIEINPMUURJODF-OAHLLOKOSA-N 2-[3-[[(1r)-1-(4-bromophenyl)ethyl]carbamoyl]-1-(2-chlorophenyl)-5-(4-chlorophenyl)pyrazol-4-yl]acetic acid Chemical compound N([C@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=1CC(O)=O)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 XIEINPMUURJODF-OAHLLOKOSA-N 0.000 claims 1
- IIXJQJVDFVHSCR-FCXZQVPUSA-N C[C@H](C(C=C1)=CC(Cl)=C1F)NC.OC(C(C(CC1=NN=NN1)=C1C(C=C2)=CC=C2Cl)=NN1C(C=CC=C1)=C1Cl)=O Chemical compound C[C@H](C(C=C1)=CC(Cl)=C1F)NC.OC(C(C(CC1=NN=NN1)=C1C(C=C2)=CC=C2Cl)=NN1C(C=CC=C1)=C1Cl)=O IIXJQJVDFVHSCR-FCXZQVPUSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- ZPKGALGAAPEZPS-OAHLLOKOSA-N N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 Chemical compound N([C@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 ZPKGALGAAPEZPS-OAHLLOKOSA-N 0.000 claims 1
- DCJYTZRLZIIFAO-OAHLLOKOSA-N N([C@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 Chemical compound N([C@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)F)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 DCJYTZRLZIIFAO-OAHLLOKOSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- QTJMKOMANNLMQO-CQSZACIVSA-N n-[(1r)-1-(4-chloro-3-fluorophenyl)ethyl]-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2h-tetrazol-5-ylmethyl)pyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(F)C(Cl)=CC=1)C(=O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1CC=1N=NNN=1 QTJMKOMANNLMQO-CQSZACIVSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625197.9 | 2006-12-18 | ||
| GB0625197A GB0625197D0 (en) | 2006-12-18 | 2006-12-18 | Cannabinoid receptor modulators |
| GB0717998A GB0717998D0 (en) | 2007-09-14 | 2007-09-14 | Canabinoid receptor modulators |
| GB0717998.9 | 2007-09-14 | ||
| PCT/GB2007/004831 WO2008075012A1 (en) | 2006-12-18 | 2007-12-17 | Cb1 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513435A JP2010513435A (ja) | 2010-04-30 |
| JP2010513435A5 true JP2010513435A5 (enExample) | 2011-02-10 |
| JP5437812B2 JP5437812B2 (ja) | 2014-03-12 |
Family
ID=39156232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542200A Expired - Fee Related JP5222855B2 (ja) | 2006-12-18 | 2007-12-17 | Ｃｂ１受容体のモジュレーター |
| JP2009542195A Expired - Fee Related JP5437812B2 (ja) | 2006-12-18 | 2007-12-17 | Ｃｂ１受容体モジュレーター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542200A Expired - Fee Related JP5222855B2 (ja) | 2006-12-18 | 2007-12-17 | Ｃｂ１受容体のモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8148404B2 (enExample) |
| EP (2) | EP2121659B1 (enExample) |
| JP (2) | JP5222855B2 (enExample) |
| CN (1) | CN103145620A (enExample) |
| AU (2) | AU2007336068B2 (enExample) |
| BR (1) | BRPI0720732A2 (enExample) |
| CA (2) | CA2673177A1 (enExample) |
| EA (1) | EA017170B1 (enExample) |
| IL (2) | IL198989A0 (enExample) |
| MX (1) | MX2009006214A (enExample) |
| NZ (1) | NZ578063A (enExample) |
| WO (3) | WO2008075013A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US7977358B2 (en) | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| MX2010006109A (es) * | 2007-12-10 | 2010-09-10 | 7Tm Pharma As | Moduladores de receptores de canabinoides. |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| EP3028683B1 (en) | 2011-07-14 | 2018-05-09 | Cook Medical Technologies LLC | A kit to be used in the treatment of obstructive sleep apnea |
| US9710644B2 (en) | 2012-02-01 | 2017-07-18 | Servicenow, Inc. | Techniques for sharing network security event information |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| EP2908770B1 (en) | 2012-10-16 | 2019-04-24 | Cook Medical Technologies LLC | Apparatus for treating obstructive sleep apnea (osa) |
| EP3027149B1 (en) | 2013-08-01 | 2019-04-10 | Cook Medical Technologies LLC | Tissue adjustment implant |
| CN105392433B (zh) | 2013-08-05 | 2019-02-19 | 库克医学技术有限责任公司 | 具有可释放管状构件的医疗装置及其使用方法 |
| CN104906682A (zh) | 2014-01-24 | 2015-09-16 | 史蒂文·沙勒布瓦 | 铰接气囊导管及其使用方法 |
| US9974563B2 (en) | 2014-05-28 | 2018-05-22 | Cook Medical Technologies Llc | Medical devices having a releasable member and methods of using the same |
| US9913661B2 (en) | 2014-08-04 | 2018-03-13 | Cook Medical Technologies Llc | Medical devices having a releasable tubular member and methods of using the same |
| CN111093572A (zh) | 2017-06-29 | 2020-05-01 | 库克医学技术有限责任公司 | 用于重新定位组织的可植入医疗装置 |
| EP3840852B1 (en) * | 2018-08-20 | 2023-10-04 | Bessor Pharma, LLC | Process for the production of cannabinoids |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| JP2003512357A (ja) | 1999-10-18 | 2003-04-02 | ユニバーシティ オブ コネチカット | カンナビノイドレセプタ拮抗物質としてのピラゾール誘導体 |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| EP1268435B1 (en) * | 2000-03-23 | 2006-11-22 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity |
| ATE358481T1 (de) * | 2001-02-28 | 2007-04-15 | Merck & Co Inc | Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten |
| CA2457922A1 (en) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| FR2831883B1 (fr) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| NZ540515A (en) * | 2002-12-02 | 2008-01-31 | Astellas Pharma Inc | Pyrazole derivatives useful as COX-I inhibitors |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| JP4041153B2 (ja) * | 2003-05-07 | 2008-01-30 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドとその使用 |
| FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
| DE602005016082D1 (de) | 2004-02-20 | 2009-10-01 | Astrazeneca Ab | 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen |
| FR2867685B1 (fr) * | 2004-03-17 | 2008-05-23 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive |
| JP2008525404A (ja) | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療剤 |
| EP1928859A1 (en) * | 2005-06-17 | 2008-06-11 | Carex SA | Pyrazole derivates as cannabinoid receptor modulators |
| CN101437398A (zh) * | 2006-03-10 | 2009-05-20 | 詹里恩探索公司 | 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂 |
-
2007
- 2007-12-17 AU AU2007336068A patent/AU2007336068B2/en not_active Ceased
- 2007-12-17 US US12/518,446 patent/US8148404B2/en not_active Expired - Fee Related
- 2007-12-17 BR BRPI0720732-8A patent/BRPI0720732A2/pt not_active IP Right Cessation
- 2007-12-17 EA EA200900838A patent/EA017170B1/ru not_active IP Right Cessation
- 2007-12-17 WO PCT/GB2007/004835 patent/WO2008075013A1/en not_active Ceased
- 2007-12-17 WO PCT/GB2007/004842 patent/WO2008075019A1/en not_active Ceased
- 2007-12-17 AU AU2007336061A patent/AU2007336061B2/en not_active Ceased
- 2007-12-17 EP EP07848579.4A patent/EP2121659B1/en not_active Not-in-force
- 2007-12-17 JP JP2009542200A patent/JP5222855B2/ja not_active Expired - Fee Related
- 2007-12-17 CA CA002673177A patent/CA2673177A1/en not_active Abandoned
- 2007-12-17 JP JP2009542195A patent/JP5437812B2/ja not_active Expired - Fee Related
- 2007-12-17 CA CA002673359A patent/CA2673359A1/en not_active Abandoned
- 2007-12-17 MX MX2009006214A patent/MX2009006214A/es active IP Right Grant
- 2007-12-17 WO PCT/GB2007/004831 patent/WO2008075012A1/en not_active Ceased
- 2007-12-17 CN CN2012103916453A patent/CN103145620A/zh active Pending
- 2007-12-17 NZ NZ578063A patent/NZ578063A/en not_active IP Right Cessation
- 2007-12-17 EP EP07848570.3A patent/EP2121617B1/en not_active Not-in-force
- 2007-12-17 US US12/519,432 patent/US8124634B2/en not_active Expired - Fee Related
-
2009
- 2009-05-27 IL IL198989A patent/IL198989A0/en unknown
- 2009-05-27 IL IL198990A patent/IL198990A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513435A5 (enExample) | ||
| JP2010513438A5 (enExample) | ||
| US7524868B2 (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| JP4693787B2 (ja) | Ｃｂ１拮抗活性を有する１，３，５−三置換４，５−ジヒドロ−１ｈ−ピラゾール誘導体 | |
| JP5378988B2 (ja) | ５員環へテロ環誘導体及びその医薬用途 | |
| AU754771B2 (en) | Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them | |
| JP2019031560A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| PT868420E (pt) | Derivados de 3-pirazole-carboxamida tendo afinidade com o receptor dos canabinoides | |
| KR102212981B1 (ko) | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 | |
| JP2009523812A5 (enExample) | ||
| JP2006316054A (ja) | 高コンダクタンス型カルシウム感受性ｋチャネル開口薬 | |
| JP2006328073A5 (enExample) | ||
| WO2008023783A1 (en) | Amine compound | |
| JP2013533283A (ja) | Ｇｐｒ４０のアゴニスト | |
| JP2006525298A5 (enExample) | ||
| JPH089541B2 (ja) | ピラゾール類を主成分とする脳浮腫抑制剤 | |
| JPWO2020252240A5 (enExample) | ||
| EA200970582A1 (ru) | ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH | |
| JP2009519903A5 (enExample) | ||
| JP2018529744A5 (enExample) | ||
| PT868364E (pt) | Metodo para formar uma embalagem de abertura facil para uma pluralidade de recipientes | |
| JP2009501745A5 (enExample) | ||
| JP2010513489A5 (enExample) | ||
| ES2326952B1 (es) | Hidratos de (rac) -n-piperidinil-5-(4-clorofenil)-1-(2,4-diclorofenil)4,5-dihidro-1h-pirazol-3-carboxamida. |